MAPK3 and breast carcinoma: In addition, phosphorylation of both ERK1 and ERK2 is significantly inhibited by dasatinib, demonstrating that the classic MAPK signaling is involved in the dasatinib-mediated inhibition of breast cancer growth and metastasis.